|
|
Article: IGEN Takes Steps to Maximize Diagnostic Market Opportunities Following Expected Termination of Roche License; Establishing Team to Manage Transfer of Roche Products And Improvements to IGEN.
- Article from:
- PR Newswire
- Article date:
- March 7, 2002
CopyrightCOPYRIGHT 2002 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
GAITHERSBURG, Md. -- IGEN International, Inc. , in response to numerous inquiries from customers and investors, announced today that it is pursuing a range of actions to maximize the value of its proprietary ORIGEN(R) technology both before and after the expected termination of the existing license agreement with Roche Diagnostics, a division of F. Hoffmann-La Roche (BULLETIN BOARD: RHHBY) . As contemplated by the final judgment issued last month by the U.S. District Court for the District of Maryland, IGEN has notified Roche that the license agreement terminates immediately once the final judgment is affirmed by the Court of Appeals. Roche developed its Elecsys(R) ...
Related newspaper, magazine, and journal articles:
|
|
Article: IGEN rests dase against Roche.(Brief Article)
BIOTECH Patent News;
November 1, 2001 ;
700+ words
... ... executives, four expert witnesses, and Roche senior executives supporting IGEN's allegations in the case. Roche is set to begin its case on November ... important claims being asserted against Roche. IGEN develops and markets biological detection ...
|
|